BioVie Inc. Warrant financials
$0.2800−6.67%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$5.7M | -$5.4M | -$6.3M | -$5.3M |
| Net income | -$5.6M | -$5.3M | -$6.1M | -$5.1M |
| Net margin | — | — | — | — |
| Diluted EPS | $-0.68 | $-0.70 | $-0.77 | $-0.98 |
| EBITDA | -$5.7M | -$5.3M | -$6.2M | -$5.2M |
| Operating cash flow | -$4.1M | -$7.4M | -$4.4M | -$3.0M |
| Free cash flow | -$4.1M | -$7.4M | -$4.4M | -$3.0M |
| Diluted shares | 8.3M | 7.5M | 7.9M | 5.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $9.0M | $13.1M | $20.5M | $25.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $14.3M | $17.5M | $22.5M | $26.8M |
| Total liabilities | $4.0M | $1.9M | $3.2M | $1.9M |
| Shareholders' equity | $10.3M | $15.6M | $19.3M | $24.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology